Sarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide

Rhea-AI Summary

Sarissa Capital Management announced a significant victory against the Amarin Corporation board, claiming to have received nearly 80% of shareholder votes in favor of their slate. This vote represents more than 100 million additional votes than the incumbent board. Sarissa, the largest shareholder, expresses confidence in leveraging Vascepa, a unique and beneficial drug, to unlock shareholder value. Sarissa emphasizes the importance of running Amarin for the benefit of all shareholders and urges further action.

Positive

• Sarissa Capital received nearly 80% of shareholder votes, indicating strong support.
• Sarissa Capital is Amarin's largest shareholder, positioning them to influence future company direction.
• Confidence expressed in leveraging Vascepa's beneficial profile to unlock shareholder value.

Negative

• None.

Sarissa honored to have received 100 million more votes than Amarin board

GREENWICH, Conn.--(BUSINESS WIRE)-- Sarissa Capital Management LP today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):

Amarin shareholders have sent a loud and clear message repudiating the incumbent Amarin board. Sarissa thanks fellow shareholders for their support in a resounding victory against the Amarin board. Our estimate is that up to nearly 80% of shareholder votes were in support of Sarissa. As Amarin’s largest shareholder, we are grateful for the opportunity to remake Amarin for the benefit of all shareholders.

Vascepa, the foundation on which Amarin is built, is a tremendous drug that is compelling for patients and payors – a unique proposition for a drug. While there is a lot of work to be done, we remain confident in our ability to leverage Vascepa’s rare and highly beneficial profile to unlock tremendous value for all shareholders.

LET’S GET TO WORK AND FINALLY BEGIN RUNNING AMARIN FOR THE BENEFIT OF ALL SHAREHOLDERS!

Additional Information

Sarissa Capital Management LP (“Sarissa Capital”), together with other participants, filed a definitive proxy statement and an accompanying blue proxy card with the SEC on January 31, 2023, in connection with the solicitation of shareholders of Amarin Corporation plc (the “Company”) at the general meeting of the Company for the election of Sarissa Capital’s slate of highly-qualified nominees (the “General Meeting”). Shareholders are advised to read the definitive proxy statement and other relevant documents related to the General Meeting as they contain important information.

The definitive proxy statement and other relevant documents are available at no charge on the SEC’s website at www.sec.gov and at www.freeamarin.com. The definitive proxy statement and other relevant documents are also available at no charge by directing a request to Sarissa Capital’s proxy solicitor, D.F. King & Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: (800) 331-7024).

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005961/en/

Dayna Packes

Sarissa Capital Management LP

info@sarissacap.com

#FreeAmarin

Source: Sarissa Capital Management LP

FAQ

What percentage of votes did Sarissa Capital receive from Amarin shareholders?

Sarissa Capital received nearly 80% of shareholder votes.

What is the relationship between Sarissa Capital and Amarin Corporation?

Sarissa Capital is the largest shareholder of Amarin Corporation.

What is Vascepa and why is it important to Amarin?

Vascepa is a medication that Sarissa believes has a unique and beneficial profile, crucial for unlocking shareholder value.

When was the proxy statement filed by Sarissa Capital regarding Amarin?

The definitive proxy statement was filed on January 31, 2023.

What does Sarissa Capital intend to do after winning the votes in Amarin?

Sarissa Capital intends to run Amarin for the benefit of all shareholders.